GAD1 and type 1 diabetes mellitus: Dedicated T1D agents, such as the anti-CD3 monoclonals teplizimab and otilixizumab (29, 30), as well as GAD-alum (Diamyd) have shown great promise in terms of C-peptide preservation in phase 2 trials but failed to meet endpoints in phase 3 development.